- Home
- IBOC vs ICUI Comparison
IBOC vs ICUI Comparison
Compare IBOC & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBOC | ICUI |
|---|---|---|
| Founded | 1966 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.6B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | IBOC | ICUI |
|---|---|---|
| Price | $67.66 | $146.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $179.50 |
| AVG Volume (30 Days) | ★ 314.9K | 216.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 5.13 | N/A |
| EPS | ★ 6.76 | N/A |
| Revenue | $821,716,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.15 | ★ N/A |
| Revenue Growth | ★ 2.80 | N/A |
| 52 Week Low | $54.11 | $107.00 |
| 52 Week High | $73.66 | $175.51 |
Technical Indicators
Market Signals| Indicator | IBOC | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 57.45 |
| Support Level | $67.61 | $146.11 |
| Resistance Level | $69.62 | $148.55 |
| Average True Range (ATR) | 1.71 | 3.55 |
| MACD | -0.47 | -0.59 |
| Stochastic Oscillator | 3.23 | 64.38 |
Price Performance
Historical ComparisonAbout IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.